Medical device and drug developer Abbott Laboratories said Monday that its MitraClip system used to repair heart valve problems was still durable in patients two years after treatment, according to study data.
The company is developing the Mitral system to repair leaky heart valves. The latest results include two years of data from the continuing. Abbott has already presented similar positive one-year results.
The MitraClip system is inserted through a catheter placed in the patient's leg. It clips together leaflets of the heart's mitral valve, which is between the left upper and lower chambers, to reduce significant mitral regurgitation. That happens when the valve leaflets do not close completely and cause blood to flow backward into the heart's left atrium. Significant mitral regurgitation can lead to an irregular heartbeat, heart failure, a stroke or heart attack over time.
The MitraClip system is approved in Europe, and Abbott expects regulatory review in the U.S. in 2011.
In the latest two-year study results, the company said 78 percent of patients with the device did not need surgery after two years. Meanwhile, patients with the device had a clinical success rate of 51.7 percent, compared with 66.3 percent of patients receiving heart surgery. Data from the study were published in The New England Journal of Medicine and presented at the American College of Cardiology's 60th Annual Scientific Session and i2 Summit 2011 in New Orleans.
Shares of Abbott rose $1.03, or 2.1 percent, to $50.40 in afternoon trading.